Vanda Pharmaceuticals Inc Total Liabilities
Vanda Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has total liabilities worth $161.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vanda Pharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vanda Pharmaceuticals Inc (2004–2025)
Total liabilities of Vanda Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Vanda Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Vanda Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Vanda Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anaergia Inc
TO:ANRG
|
Canada | CA$195.05 Million |
|
Hansae Co
KO:105630
|
Korea | ₩855.67 Billion |
|
Ananti Inc
KQ:025980
|
Korea | ₩847.31 Billion |
|
Pact Group Holdings Ltd
AU:PGH
|
Australia | AU$1.55 Billion |
|
Imperial Petroleum Inc
NASDAQ:IMPP
|
USA | $58.14 Million |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
USA | $20.04 Million |
|
Prakash Industries Limited
NSE:PRAKASH
|
India | Rs11.38 Billion |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
Spain | €138.18 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Vanda Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VNDA total asset value.
Liquidity & Leverage Metrics
Vanda Pharmaceuticals Inc Total Liabilities Ratios Explained
Vanda Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vanda Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual total liabilities of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $161.76 Million | +37.48% |
| 2024-12-31 | $117.66 Million | +13.65% |
| 2023-12-31 | $103.53 Million | -3.29% |
| 2022-12-31 | $107.05 Million | +20.46% |
| 2021-12-31 | $88.86 Million | +10.82% |
| 2020-12-31 | $80.19 Million | +10.15% |
| 2019-12-31 | $72.80 Million | +28.38% |
| 2018-12-31 | $56.71 Million | -23.41% |
| 2017-12-31 | $74.04 Million | -6.33% |
| 2016-12-31 | $79.04 Million | -1.22% |
| 2015-12-31 | $80.02 Million | +635.03% |
| 2014-12-31 | $10.89 Million | -89.03% |
| 2013-12-31 | $99.22 Million | -20.96% |
| 2012-12-31 | $125.54 Million | -15.82% |
| 2011-12-31 | $149.14 Million | -14.96% |
| 2010-12-31 | $175.37 Million | -13.48% |
| 2009-12-31 | $202.68 Million | +5078.99% |
| 2008-12-31 | $3.91 Million | -70.20% |
| 2007-12-31 | $13.13 Million | +38.18% |
| 2006-12-31 | $9.50 Million | +86.78% |
| 2005-12-31 | $5.09 Million | +181.31% |
| 2004-12-31 | $1.81 Million | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more